Form 4: Opus Genetics COO Joseph Schachle Receives Stock and Option Grants

Chief Operating Officer of Opus Genetics, Joseph Schachle, reports the acquisition of restricted stock units and stock options.

Summary

• Joseph K Schachle, the Chief Operating Officer of Opus Genetics, reported changes in his beneficial ownership of the company's securities.
• On March 13, 2025, Schachle acquired 52,500 shares of common stock through a grant of restricted stock units.
• These restricted stock units vest in four equal installments annually, starting on March 13, 2026, contingent upon his continued service.
• Additionally, Schachle acquired options to purchase 52,500 shares of common stock at an exercise price of $0.93.
• These options vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly over the following 12 quarters, also subject to continued service.
• Following these transactions, Schachle directly owns 54,500 shares of common stock and options for 52,500 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The vesting schedules suggest a long-term commitment from the executive.

Positives

• The grant of restricted stock units and stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grants incentivize the COO to work towards increasing shareholder value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates